- $10.72bn
- $9.66bn
- $2.32bn
Annual income statement for Exelixis, fiscal year end - January 3rd, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 30th | 2023 December 29th | 2025 December 31st | 2025 January 3rd | |
|---|---|---|---|---|---|
| Period Length: | 52 W | 52 W | 52 W | 52 W | 53 W |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,435 | 1,611 | 1,830 | 2,320 | 2,169 |
| Cost of Revenue | |||||
| Gross Profit | 1,382 | 1,553 | 1,758 | 2,236 | 2,092 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1,148 | 1,410 | 1,659 | 1,448 | 1,564 |
| Operating Profit | 287 | 201 | 171 | 872 | 605 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 294 | 234 | 258 | 941 | 682 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 231 | 182 | 208 | 783 | 521 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 231 | 182 | 208 | 783 | 521 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 231 | 182 | 208 | 783 | 521 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.717 | 0.562 | 0.646 | 2.84 | 1.98 |